Market Cap
$76.9B
MRNA
Moderna, Inc.
$188.77 ▼ -0.09%
Prev close $188.94Market cap$76.9B
ConsensusSell
12-mo target$120.67 (-36.1%)
▲ Neutral
Analyst conviction 4/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)33 New Institutional Positions17 Institutional ExitsCongressional Activity (2) Biotech & Drug Discovery
Snapshot
The big-picture read on MRNA right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Hold (37%)
Inst. Holders
50 funds
Inst. Value
$20.9B
Inst. Activity
33 buys / 17 sells
Insider Activity
$0.00 buy / $49.2M sell
Insider Net $
-$49.2M
Social Sentiment
43° Neutral
SEC Reports
18
Congressional
2 trades
Price chart 30d +25.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Sep 30, 2026 SEC Short Volume: MRNA — 61.4% short (4.6M / 7.5M)
Short: 4,599,954 | Exempt: 4,864 | TRF Vol: 7,496,860 | Short Ratio: 61.4% | Off-exchange volume (da
Citigroup double downgrade: Neutral → Sell
ANALYST-DOWNGRADE — Impact 4/10
Sep 15, 2026 Insider
Hoge Stephen acquired via exercise 76,452 shares
President @ $12.21 ($933.5K)
Sep 15, 2026 Insider
Hoge Stephen sold 40,281 shares
President @ $146.07 ($5.9M)
Sep 14, 2026 Insider
Sep 3, 2026 SEC Hoge Stephen sold 40,294 shares
President @ $144.13 ($5.8M)
Rothschild & Co double downgrades MRNA to Sell — PT $81 (-46.3%) from $40
ANALYST-DOWNGRADE — Impact 6/10
Aug 31, 2026 Event
Aug 25, 2026 SEC Wentz v. Moderna, Inc. et al
Court ruling (mad) — Docket: 1:24-cv-12058
Wolfe Research upgrades MRNA to Peer Perform — PT $0 (N/A%)
ANALYST-UPGRADE — Impact 1/10
Analyst ratings buy % +184.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
37% rate it Buy or better · 30 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | Citigroup | DOWNGRADE | Sell | 55% |
| Sep 3, 2026 | Rothschild & Co | DOWNGRADE | Sell | 58% |
| Aug 28, 2026 | Argus Research | UPGRADE | Buy | 54% |
| Aug 25, 2026 | Wolfe Research | UPGRADE | Peer Perform | 52% |
| Aug 24, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| Aug 21, 2026 | JP Morgan | MAINTAIN | Underweight | 55% |
| Aug 20, 2026 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Aug 20, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Aug 20, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Aug 19, 2026 | William Blair | UPGRADE | Outperform | 51% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 17 | 2 | 0 | 37% | |
| Aug 1, 2026 | 2 | 7 | 18 | 2 | 1 | 30% | |
| Jul 1, 2026 | 0 | 4 | 19 | 4 | 3 | 13% | |
| Jun 1, 2026 | 0 | 4 | 19 | 4 | 3 | 13% | |
| May 1, 2026 | 2 | 7 | 18 | 2 | 1 | 30% | |
| Apr 1, 2026 | 0 | 3 | 21 | 3 | 3 | 10% | |
| Mar 1, 2026 | 0 | 3 | 21 | 3 | 3 | 10% | |
| Feb 1, 2026 | 0 | 3 | 21 | 3 | 3 | 10% |
Price targets
Where 18 covering analysts think MRNA trades over the next 12 months.
$120.67 -36.1% upside Strong Sell
Current$188.85 Low$45.00 Median$125.00 High$170.00 18 analysts
$45.00$170.00
Analyst rating Hold· 2.8/5 as of Oct 2, 2026
Social media sentiment mood -31.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Health Savings Account in Healthcare stocks
▲ 1 · 💬 4· ⚡ 1.8
$10k -> +$94k (~4 months “investing”)
▲ 1 · 💬 7· ⚡ 0.5
I think I finally understand why I lost so much money in stocks
▲ 1 · 💬 7· ⚡ 0.5
$FWRD: I’ve detected the overnight accumulation before the move. And it’s loading harder into the pull back RN
▲ 1 · 💬 6· ⚡ 0.5
MRNA at $150+ — who’s still shorting this, and who thinks the squeeze has more room?
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 1 bullish, 5 bearish, 3 mixed, 9 neutral · avg impact 3.6/10.
BEARISHANALYST-DOWNGRADE4/10
Citigroup double downgrade: Neutral → Sell
Sep 30, 2026
BEARISHANALYST-DOWNGRADE6/10
Rothschild & Co double downgrades MRNA to Sell — PT $81 (-46.3%) from $40
Sep 3, 2026
MIXEDANALYST-UPGRADE1/10
Wolfe Research upgrades MRNA to Peer Perform — PT $0 (N/A%)
Aug 25, 2026
MIXEDANALYST-UPGRADE1/10
William Blair upgrades MRNA to Outperform — PT $N/A (N/A%)
Aug 20, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: MRNA — 61.4% short (4.6M / 7.5M)
Short: 4,599,954 | Exempt: 4,864 | TRF Vol: 7,496,860 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: MRNA — 57.7% short (5.2M / 9.0M)
Short: 5,172,174 | Exempt: 29,139 | TRF Vol: 8,961,498 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: MRNA — 62.8% short (4.4M / 6.9M)
Short: 4,364,990 | Exempt: 4,642 | TRF Vol: 6,947,377 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: MRNA — 61.8% short (3.6M / 5.9M)
Short: 3,649,672 | Exempt: 14,792 | TRF Vol: 5,910,395 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: MRNA — 60.8% short (4.4M / 7.2M)
Short: 4,396,411 | Exempt: 8,087 | TRF Vol: 7,230,900 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.27 | $-3.32–$-0.53 | -150.0% | +5.3% | 4↑ 0↓ | $0.9B | 15 |
| Next Q | $-1.75 | $-2.09–$-0.63 | 17.2% | +6.2% | 5↑ 0↓ | $0.7B | 14 |
| Current FY | $-8.39 | $-10.55–$-6.66 | -15.5% | +1.7% | 7↑ 1↓ | $2.1B | 21 |
| Next FY | $-4.79 | $-7.11–$-2.73 | 42.9% | +2.4% | 6↑ 4↓ | $2.4B | 20 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.275 | — |
| 7d ago | $-1.289 | +0.014 |
| 30d ago | $-1.346 | +0.072 |
| 60d ago | $-1.485 | +0.210 |
| 90d ago | $-1.129 | -0.146 |
Institutional ownership
Which big funds own MRNA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $20.9B total value (298,041,455 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, VANGUARD. Net buying activity: 33 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 51,859,891 | $3.6B | 17.4% | — |
| BlackRock, Inc. | 30,599,409 | $2.1B | 10.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 23,208,792 | $1.6B | 7.8% | — |
| Capital World Investors | 22,276,996 | $1.6B | 7.5% | — |
| BAILLIE GIFFORD & CO | 18,206,778 | $1.3B | 6.1% | — |
| STATE STREET CORP | 15,726,193 | $1.1B | 5.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15,581,313 | $1.1B | 5.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 9,710,335 | $678.8M | 3.3% | — |
| MORGAN STANLEY | 9,538,094 | $668.0M | 3.2% | — |
| TWO SIGMA INVESTMENTS, LP | 7,193,530 | $503.8M | 2.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | TRIM | 6,603,697 | 4,671,950 | -29.3% | $327.2M |
| NORGES BANK | NEW | — | 3,026,074 | — | $211.9M |
| CITIGROUP INC | ADD | 1,480,034 | 2,165,414 | +46.3% | $151.6M |
| BAMCO INC /NY/ | NEW | — | 1,989,386 | — | $139.3M |
| BANK OF AMERICA CORP /DE/ | ADD | 986,360 | 1,409,679 | +42.9% | $98.7M |
| Qube Research & Technologies Ltd | ADD | 700,692 | 907,157 | +29.5% | $63.5M |
| JPMORGAN CHASE & CO | TRIM | 1,317,601 | 837,452 | -36.4% | $59.5M |
| RHUMBLINE ADVISERS | ADD | 560,359 | 809,853 | +44.5% | $56.7M |
| Nuveen, LLC | TRIM | 1,078,194 | 762,777 | -29.3% | $53.4M |
| HSBC HOLDINGS PLC | ADD | 490,088 | 636,199 | +29.8% | $45.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 50 transactions. Net -$49.2M — $0.00 bought, $49.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Hoge Stephen | President | EXERCISE | 76,452 | $12.21 | $933.5K |
| Sep 15, 2026 | Hoge Stephen | President | SELL | 40,281 | $146.07 | $5.9M |
| Sep 14, 2026 | Hoge Stephen | President | SELL | 40,294 | $144.13 | $5.8M |
| Sep 14, 2026 | Hoge Stephen | President | EXERCISE | 76,453 | $12.21 | $933.5K |
| Sep 10, 2026 | Mock James M | Chief Financial Officer | SELL | 19,836 | $134.49 | $2.7M |
| Sep 10, 2026 | Mock James M | Chief Financial Officer | SELL | 15,000 | $134.49 | $2.0M |
| Sep 10, 2026 | Mock James M | Chief Financial Officer | EXERCISE | 19,836 | $30.96 | $614.1K |
| Sep 4, 2026 | Mock James M | Chief Financial Officer | EXERCISE | 11,797 | — | — |
| Sep 4, 2026 | Mock James M | Chief Financial Officer | TAX W/H | 5,704 | $148.87 | $849.2K |
| Sep 4, 2026 | Klinger Shannon Thyme | Chief Legal Officer | EXERCISE | 11,797 | — | — |
Congressional trades
MRNA trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Maria Elvira Salazar | R | HOUSE | SELL | $1,001 - $15,000 | Moderna Inc | Sep 10, 2026(23d) |
| Aug 19, 2026 | Maria Elvira Salazar | R | HOUSE | BUY | $1,001 - $15,000 | Moderna Inc | Sep 10, 2026(23d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MRNA.
Shares short
32,872,787
Settlement Sep 15, 2026
Change vs prior
-16.0%
Semi-monthly cycle
Days to cover
2.5
At avg daily volume
Of shares outstanding
≈8.2%
Estimate — not % of float
All MRNA filing & press-release reports (18)
- Citigroup double downgrade: Neutral → SellSep 30, 2026
- Rothschild & Co double downgrades MRNA to Sell — PT $81 (-46.3%) from $40Sep 3, 2026
- Wolfe Research upgrades MRNA to Peer Perform — PT $0 (N/A%)Aug 25, 2026
- William Blair upgrades MRNA to Outperform — PT $N/A (N/A%)Aug 20, 2026
- COURT-RULING reportSep 2, 2026
- 144 reportAug 5, 2026
- 8-K reportJul 31, 2026
- 3 reportJul 10, 2026
- 8-K reportJul 8, 2026
- 144 reportJun 18, 2026
- COURT-RULING reportJun 17, 2026
- CLUSTER reportMay 22, 2026
- 144 reportMay 21, 2026
- 144 reportMay 8, 2026
- COURT-RULING reportMar 30, 2026
- DEFA14A reportMar 16, 2026
- 8-K reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026